@rgfrank.bsky.social
Last wee Ben Graham and I released a paper examining R&D spending by large pharmaceutical manufacturers. We show that the evidence does not support the idea that R&D effort has declined as a result of the Inflation Reduction Act. In fact the evidence suggests that if anything, it has increased.
Research and development intensity and the Inflation Reduction Act's prescription drug provisions | Brookings
www.brookings.edu
September 20, 2025 at 9:23 PM
Last wee Ben Graham and I released a paper examining R&D spending by large pharmaceutical manufacturers. We show that the evidence does not support the idea that R&D effort has declined as a result of the Inflation Reduction Act. In fact the evidence suggests that if anything, it has increased.
Christen Linke Young, Rachel Sachs and I just put out a paper reviewing issues related to adopting International Reference Prices for prescription drugs. The link is: www.brookings.edu/articles/int...
International reference pricing for prescription drugs | Brookings
Christen Linke Young, Richard Frank, and Rachel Sachs explore the potential role of international prices in the U.S. drug policy today.
www.brookings.edu
July 14, 2025 at 11:40 AM
Christen Linke Young, Rachel Sachs and I just put out a paper reviewing issues related to adopting International Reference Prices for prescription drugs. The link is: www.brookings.edu/articles/int...
Sherry Glied and I posted a blog noting that cuts to NIH and FDA are grounded in misunderstanding of the basis for grant programs and a failure to consider the health impacts of staff reductions at FDA. See www.brookings.edu/articles/the...
The Trump administration's NIH and FDA cuts will negatively impact patients
Additional cuts in funding and staffing at the NIH and FDA could portend serious risks to the American public.
www.brookings.edu
May 17, 2025 at 7:54 PM
Sherry Glied and I posted a blog noting that cuts to NIH and FDA are grounded in misunderstanding of the basis for grant programs and a failure to consider the health impacts of staff reductions at FDA. See www.brookings.edu/articles/the...
My colleague Yihan Shi and I posted the linked paper showing that all prescription drugs slated for Medicare negotiation and likely to soon be negotiated are making healthy returns on R&D investments. www.brookings.edu/articles/cum...
Cumulative net earnings of drugs selected or likely to be selected for negotiation
Richard Frank and Yihan Shi investigate the net sales of drugs selected for the second round of negotiation and future drug selections.
www.brookings.edu
May 14, 2025 at 6:08 PM
My colleague Yihan Shi and I posted the linked paper showing that all prescription drugs slated for Medicare negotiation and likely to soon be negotiated are making healthy returns on R&D investments. www.brookings.edu/articles/cum...
Today Sherry Glied and I posted a commentary on Health Affairs Forefront outlining how the HHS reorganization runs counter to RFK's stated goals for the department and any notion of improved efficiency. See the post at www.healthaffairs.org/content/fore...
Trump Administration’s HHS Cuts: Creating Waste And Inefficiency, Not Eliminating Them | Health Affairs Forefront
Rather than reinvent government to better serve the American people, as his predecessors sought to do, HHS Secretary Kennedy has made government less efficient and effective.
www.healthaffairs.org
April 21, 2025 at 3:42 PM
Today Sherry Glied and I posted a commentary on Health Affairs Forefront outlining how the HHS reorganization runs counter to RFK's stated goals for the department and any notion of improved efficiency. See the post at www.healthaffairs.org/content/fore...
Today scientific American published my op ed on Medicaid cuts and the opioid epidemic. It can be found at www.scientificamerican.com/article/medi...
Medicaid Cuts Kick Down on People Caught in the Opioid Epidemic
Proposed cuts to Medicaid could undo advances in treatment for opioid use disorders, risking more overdoses, deaths and stress on the U.S. health system
www.scientificamerican.com
March 18, 2025 at 4:49 PM
Today scientific American published my op ed on Medicaid cuts and the opioid epidemic. It can be found at www.scientificamerican.com/article/medi...
I posted a paper today with so e facts to highlight
Possible consequences of Medicaid cuts www.brookings.edu/articles/the...
Possible consequences of Medicaid cuts www.brookings.edu/articles/the...
The role of Medicaid in addressing the opioid epidemic
Richard G. Frank reviews the role of Medicaid in treating opioid use disorders and the impacts of policies intended to cut funding.
www.brookings.edu
February 26, 2025 at 12:47 AM
I posted a paper today with so e facts to highlight
Possible consequences of Medicaid cuts www.brookings.edu/articles/the...
Possible consequences of Medicaid cuts www.brookings.edu/articles/the...
The following paper may be of interest to folks following the IRA nam10.safelinks.protection.outlook.com?url=https%3A...
Assessing the Effect of the Medicare Part D Redesign
This Viewpoint focuses on the Manufacturer Discount Program, identifying 4 key themes of interest to policymakers that may be affected by its Part D redesign.
nam10.safelinks.protection.outlook.com
January 11, 2025 at 9:28 PM
The following paper may be of interest to folks following the IRA nam10.safelinks.protection.outlook.com?url=https%3A...
